Institutional investors hold a majority ownership of IMGN through the 89.60% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2013, these large investors purchased a net $2.7 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
PHARUS MANAGEMENT SA Bought 8.0 Thousand shares of ImmunoGen Inc
CREATIVE PLANNING, INC. Sold 2.8 Thousand shares of ImmunoGen Inc
R. W. ROGÉ & CO., INC. Sold 4.5 Thousand shares of ImmunoGen Inc